Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
niceritrol
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Niceritrol is a niacin (nicotinic acid) derivative used as a hypolipidemic agent. It is an ester of pentaerythritol and nicotinic acid, slowly hydrolyzed in the body to release nicotinic acid. Niceritrol acts primarily by lowering cholesterol and triglyceride levels in plasma, particularly in the VLDL and LDL fractions. Its mechanism involves partial inhibition of free fatty acid release from adipose tissue and increased lipoprotein lipase activity, leading to improved lipid profiles. Additionally, it has vasodilatory properties and can inhibit platelet aggregation both directly and indirectly via lipid-lowering effects. Niceritrol has been used for treating hyperlipidemias (dyslipidemia) and peripheral vascular diseases.
- Brand names
- PerycitBufor
- Other names
- pentaerythritoltetranicotinate
02
Targets
HCAR2 (Hydroxycarboxylic acid receptor 2)FFAR (Free Fatty Acid Release from Adipose Tissue)LPL (Lipoprotein lipase)
Beyond the preview
Go deeper on niceritrol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on niceritrol.